TB Alternative Assets Ltd. Makes New $6.38 Million Investment in Moderna, Inc. (NASDAQ:MRNA)

TB Alternative Assets Ltd. bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 59,900 shares of the company’s stock, valued at approximately $6,383,000. Moderna comprises 1.6% of TB Alternative Assets Ltd.’s portfolio, making the stock its 19th largest holding.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC raised its position in Moderna by 7.5% during the fourth quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock worth $266,000 after acquiring an additional 187 shares during the last quarter. International Assets Investment Management LLC raised its position in shares of Moderna by 6,528.9% in the fourth quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock valued at $38,552,000 after buying an additional 381,808 shares during the last quarter. abrdn plc raised its position in shares of Moderna by 477.5% in the fourth quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after buying an additional 399,843 shares during the last quarter. Ontario Teachers Pension Plan Board acquired a new position in shares of Moderna in the fourth quarter valued at approximately $1,358,000. Finally, Hobbs Group Advisors LLC acquired a new position in shares of Moderna in the fourth quarter valued at approximately $664,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Oppenheimer boosted their price objective on shares of Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, June 12th. Evercore ISI assumed coverage on shares of Moderna in a research report on Tuesday, May 14th. They issued an “in-line” rating and a $120.00 price objective for the company. Canaccord Genuity Group boosted their price objective on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research report on Friday, May 3rd. Royal Bank of Canada upped their price target on shares of Moderna from $135.00 to $160.00 and gave the stock an “outperform” rating in a research report on Monday, June 3rd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 price target on shares of Moderna in a research report on Tuesday, April 9th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. According to MarketBeat, Moderna presently has a consensus rating of “Hold” and an average target price of $129.02.

Moderna Stock Performance

Shares of MRNA stock traded down $15.15 on Wednesday, hitting $122.45. The stock had a trading volume of 7,661,623 shares, compared to its average volume of 4,204,997. The stock’s 50 day moving average is $133.02 and its 200-day moving average is $111.32. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating the consensus estimate of ($3.59) by $0.52. The business had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business’s quarterly revenue was down 91.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.19 earnings per share. On average, sell-side analysts forecast that Moderna, Inc. will post -7.46 EPS for the current year.

Insider Activity

In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $101.68, for a total value of $1,525,200.00. Following the completion of the transaction, the director now directly owns 2,086,931 shares in the company, valued at $212,199,144.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $101.68, for a total value of $1,525,200.00. Following the sale, the director now directly owns 2,086,931 shares of the company’s stock, valued at $212,199,144.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Stephen Hoge sold 255 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $120.96, for a total transaction of $30,844.80. Following the completion of the sale, the president now directly owns 1,486,508 shares in the company, valued at $179,808,007.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 396,255 shares of company stock worth $54,210,631. 15.70% of the stock is currently owned by company insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.